Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:2876 |
| Name | laryngeal squamous cell carcinoma |
| Definition | A laryngeal carcinoma that has_material_basis_in squamous cells. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation cancer organ system cancer respiratory system cancer larynx cancer laryngeal carcinoma laryngeal squamous cell carcinoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT00904345 | Phase II | Cetuximab | Study of Radiation (RT) Concurrent With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (SCC) | Terminated | USA | 0 |
| NCT01467115 | Phase II | Leucovorin Cisplatin + Docetaxel + Fluorouracil Filgrastim Cetuximab | INDUCTION CHEMOTHERAPY FOLLOWED BY CETUXIMAB AND RADIATION THERAPY FOR HEAD AND NECK CANCER | Completed | USA | 0 |
| NCT01540682 | Phase I | Alisertib + Cetuximab | MLN8237 in Head and Neck Cancer | Completed | USA | 0 |
| NCT01612351 | Phase II | Carboplatin + Cisplatin + Lapatinib + Paclitaxel Carboplatin + Lapatinib + Paclitaxel | Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery | Active, not recruiting | USA | 0 |
| NCT01633541 | Phase II | AT-101 Carboplatin Cisplatin Docetaxel | Chemotherapy AND Bcl-xL Inhibitor (AT-101) For Organ Preservation In Adults With Advanced Laryngeal Cancer | Completed | USA | 0 |
| NCT01711658 | Phase II | Cisplatin + Lapatinib + Radiotherapy Cisplatin + Radiotherapy | TRYHARD: Radiation Therapy Plus Cisplatin With or Without Lapatinib in Treating Patients With Head and Neck Cancer. (TRYHARD) | Completed | USA | CAN | 0 |
| NCT01732640 | Phase Ib/II | Afatinib + Carboplatin + Paclitaxel Cisplatin | A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC. | Terminated | USA | 0 |
| NCT01758731 | Phase I | Cetuximab + Olaparib | Study of Olaparib With Radiation Therapy and Cetuximab in Advanced Head and Neck Cancer With Heavy Smoking History | Completed | USA | 0 |
| NCT01783587 | Phase I | Afatinib Docetaxel | Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer | Completed | USA | 0 |
| NCT01810913 | Phase II | Docetaxel Cisplatin Cetuximab + Docetaxel | Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer | Recruiting | USA | CAN | 1 |
| NCT01824823 | Phase II | Afatinib | Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of Recurrence | Terminated | USA | 0 |
| NCT01935921 | Phase I | Cetuximab + Ipilimumab | Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer | Completed | USA | 0 |
| NCT02107235 | Phase I | Cisplatin Rigosertib Sodium | Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer | Completed | USA | 0 |
| NCT02196168 | Phase II | Adavosertib Cisplatin | Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | Terminated | CAN | 0 |
| NCT02201355 | Phase I | Cisplatin | Reduced-Volume Hypofractionated, PET-directed Intensity Modulated Radiotherapy Concurrent With Weekly Cisplatin Chemotherapy for Squamous Cell Carcinoma of the Head and Neck | Terminated | USA | 0 |
| NCT02262741 | Phase I | Tremelimumab Durvalumab | A Phase I Study to Evaluate the Safety, Tolerability and Efficacy of MEDI4736 With Tremelimumab or Tremelimumab Alone in Head and Neck Cancer | Completed | USA | CAN | 0 |
| NCT02289209 | Phase II | Pembrolizumab | Reirradiation With MK-3475 in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck | Active, not recruiting | USA | 0 |
| NCT02296684 | Phase II | Pembrolizumab Cisplatin | Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
| NCT02334319 | Phase I | Ganetespib | Ganetespib Window of Opportunity Study in Head and Neck Cancers | Terminated | USA | 0 |
| NCT02358031 | Phase III | Cetuximab Pembrolizumab Fluorouracil Carboplatin Cisplatin | A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) | Completed | 0 | |
| NCT02381535 | Phase I | Cisplatin Onalespib | Hsp90 Inhibitor AT13387 in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and Cisplatin | Active, not recruiting | USA | CAN | 0 |
| NCT02449681 | Phase II | TH-4000 | Study for Treatment of Patients With Recurrent or Metastatic SCCHN or SCCS | Terminated | USA | AUS | 0 |
| NCT02454179 | Phase II | Pembrolizumab Acalabrutinib | Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Advanced Head and Neck Squamous Cell Carcinoma | Completed | USA | 0 |
| NCT02473731 | Phase I | CDX-3379 | A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients | Completed | USA | 0 |
| NCT02499120 | Phase II | Palbociclib Cetuximab | Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer | Completed | USA | SVK | ROU | POL | ITA | HUN | ESP | CZE | 7 |
| NCT02499328 | Phase Ib/II | Danvatirsen + Durvalumab AZD5069 + Durvalumab Durvalumab Danvatirsen | Study to Assess Combination of MEDI4736 With Either AZD9150 or AZD5069 in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck | Active, not recruiting | USA | ITA | GBR | ESP | DEU | BEL | 0 |
| NCT02551159 | Phase III | Cisplatin Durvalumab Carboplatin + Cetuximab + Fluorouracil Tremelimumab | Phase III Open Label First Line Therapy Study of MEDI 4736 With or Without Tremelimumab Versus Standard of Care (SOC) in SCCHN | Completed | USA | SVK | ROU | POL | ITA | GRC | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUT | 9 |
| NCT02555644 | Phase I | Prexasertib Cisplatin Cetuximab | A Study of LY2606368 With Chemotherapy and Radiation in Participants With Head and Neck Cancer | Completed | USA | FRA | 0 |
| NCT02573493 | Phase II | Cisplatin + Nab-paclitaxel Cetuximab + Nab-paclitaxel | Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC) | Active, not recruiting | USA | 0 |
| NCT02585973 | Phase I | Adavosertib + Cisplatin | Dose-escalating AZD1775 + Concurrent Radiation + Cisplatin for Intermediate/High Risk HNSCC | Completed | USA | 0 |
| NCT02586207 | Phase I | Cisplatin + Pembrolizumab | Pembrolizumab in Combination With CRT for LA-SCCHN | Active, not recruiting | USA | 0 |
| NCT02643550 | Phase Ib/II | Cetuximab + Monalizumab | Study of IPH2201 (Monalizumab) and Cetuximab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Completed | USA | FRA | 0 |
| NCT02734537 | Phase II | Cisplatin | Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery | Recruiting | USA | 0 |
| NCT02741570 | Phase III | Carboplatin + Cetuximab + Cisplatin + Fluorouracil Ipilimumab + Nivolumab | Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Completed | USA | POL | ITA | ISR | IRL | GRC | GBR | FRA | ESP | DEU | CHE | BRA | AUT | AUS | 4 |
| NCT02759575 | Phase Ib/II | Cisplatin + Pembrolizumab | A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma | Completed | USA | 0 |
| NCT02764593 | Phase I | Nivolumab Cisplatin + Nivolumab Cetuximab + Nivolumab | Chemotherapy +/- Nivolumab in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma | Completed | USA | 0 |
| NCT02769520 | Phase II | Pembrolizumab | Efficacy Study of Pembrolizumab in Relapsed, Locally Recurrent Squamous Cell Cancer of the Head and Neck | Active, not recruiting | USA | 0 |
| NCT02775812 | Phase I | Cisplatin + Pembrolizumab | Cisplatin, Radiation Therapy, and Pembrolizumab in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma | Completed | USA | 0 |
| NCT02892201 | Phase II | Pembrolizumab | Pembrolizumab in HNSCC With Residual Disease After Radiation | Terminated | USA | 0 |
| NCT02994069 | Phase II | Cisplatin | Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers | Active, not recruiting | USA | 0 |
| NCT03001570 | Phase II | Cetuximab + Radiotherapy | Accelerated Modulated Fractionation (SIB-IMRT) for Head and Neck District (FAMOSO) | Recruiting | ITA | 0 |
| NCT03162731 | Phase I | Ipilimumab + Nivolumab | Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients With Stage IVA-B Head and Neck Cancer | Completed | USA | 0 |
| NCT03238365 | Phase I | Nivolumab + Tadalafil Nivolumab | Nivolumab With or Without Tadalafil in Treating Patients With Recurrent Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery | Completed | USA | 0 |
| NCT03247309 | Phase I | Aldesleukin + IMA201 Cyclophosphamide + Fludarabine | TCR-engineered T Cells in Solid Tumors With Emphasis on NSCLC and HNSCC (ACTengine) (ACTengine) | Completed | USA | DEU | 0 |
| NCT03317327 | Phase Ib/II | Nivolumab | REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck Tumors (REPORT) | Recruiting | NOR | 0 |
| NCT03341936 | Phase II | Lirilumab + Nivolumab | Adjuvant Nivolumab and Lirilumab in Patients With Relapsed, Resectable Squamous Cell Carcinoma of the Head and Neck | Active, not recruiting | USA | 0 |
| NCT03342352 | Phase III | Carboplatin + Cetuximab + Cisplatin + Fluorouracil Carboplatin + Cisplatin + Epacadostat + Fluorouracil + Nivolumab Carboplatin + Cisplatin + Fluorouracil + Nivolumab | Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310) | Withdrawn | 0 | |
| NCT03342911 | Phase II | Carboplatin + Nivolumab + Paclitaxel | Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery | Completed | USA | 0 |
| NCT03349710 | Phase III | Cetuximab Cisplatin Cetuximab + Nivolumab Cisplatin + Nivolumab | Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer | Completed | USA | TUR | POL | ITA | FRA | ESP | 4 |
| NCT03356223 | Phase II | Abemaciclib | Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6 (ABORL) | Completed | FRA | 0 |
| NCT03370276 | Phase Ib/II | Cetuximab + Nivolumab | Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
| NCT03381183 | Phase Ib/II | Cyclophosphamide + Durvalumab + Tremelimumab | IRX-2 Regimen, Durvalumab, Tremelimumab for Incurable Head and Neck Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
| NCT03383094 | Phase II | Pembrolizumab Cisplatin + Radiotherapy | Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer | Recruiting | USA | 0 |
| NCT03386838 | Phase III | Linrodostat + Nivolumab Carboplatin + Cetuximab + Cisplatin + Fluorouracil | An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck | Withdrawn | USA | 0 |
| NCT03389477 | Phase II | Cisplatin + Palbociclib Cetuximab + Palbociclib | Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
| NCT03406247 | Phase II | Ipilimumab + Nivolumab Nivolumab | Immunotherapy in Head and Neck Squamous Cell Carcinoma : Phase 2 Trial Evaluating the Efficacy and the Toxicity of Nivolumab Alone, and of the Combination Nivolumab and Ipilimumab (ADJORL1) | Recruiting | FRA | 0 |
| NCT03480672 | Phase II | Cisplatin Cisplatin + Pembrolizumab | Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma | Active, not recruiting | DEU | 0 |
| NCT03524326 | Phase I | Cetuximab + Lenvatinib | Testing Lenvatinib and Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma and Cutaneous Squamous Cell Carcinoma | Completed | USA | 0 |
| NCT03539198 | Phase 0 | Nivolumab | Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer | Terminated | USA | 0 |
| NCT03576417 | Phase III | Cisplatin Cisplatin + Nivolumab | A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck (NIVOPOSTOP) | Active, not recruiting | FRA | 0 |
| NCT03625323 | Phase II | Eftilagimod alpha + Pembrolizumab | Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC (TACTI-002) | Active, not recruiting | USA | GBR | ESP | AUS | 1 |
| NCT03635164 | Phase I | Durvalumab | Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
| NCT03719690 | Phase II | Tipifarnib | Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy (AIM-HN/SEQ-HN) | Completed | USA | NOR | NLD | ITA | GRC | GBR | ESP | DNK | DEU | BEL | AUT | AUS | 4 |
| NCT03723967 | Phase II | Carboplatin + Durvalumab + Paclitaxel | FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel (FRAIL-IMMUNE) | Completed | FRA | 0 |
| NCT03818061 | Phase II | Atezolizumab + Bevacizumab | Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck (ATHENA) | Active, not recruiting | FRA | 0 |
| NCT03818542 | Phase I | ABBV-927 ABBV-368 Budigalimab | A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma | Terminated | USA | 0 |
| NCT03821935 | Phase I | ABBV-151 ABBV-151 + Budigalimab | Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | ISR | FRA | ESP | CAN | BEL | AUS | 4 |
| NCT03865082 | Phase II | IMO-2125 + Ipilimumab + Nivolumab | Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) | Active, not recruiting | USA | 0 |
| NCT03894891 | Phase II | Cisplatin + Docetaxel + Nivolumab | Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer | Completed | USA | 0 |
| NCT03906526 | Phase I | Motolimod Motolimod + Nivolumab Nivolumab | A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer | Terminated | USA | 0 |
| NCT03944915 | Phase II | Carboplatin + Nivolumab + Paclitaxel Cisplatin + Filgrastim + Fluorouracil + Hydroxyurea + Paclitaxel | De-Escalation Therapy for Human Papillomavirus Negative Disease (DEPEND) | Recruiting | USA | 0 |
| NCT04030455 | Phase II | Cisplatin + Docetaxel + Pembrolizumab Carboplatin + Docetaxel + Pembrolizumab | Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer | Active, not recruiting | USA | 0 |
| NCT04080804 | Phase II | Nivolumab Nivolumab + Relatlimab Ipilimumab + Nivolumab | Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer | Recruiting | USA | 0 |
| NCT04096638 | Phase I | Nivolumab + SB 11285 SB 11285 | Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors | Completed | USA | 0 |
| NCT04128696 | Phase III | Pembrolizumab GSK3359609 + Pembrolizumab | Study of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (INDUCE-3) | Terminated | USA | ROU | POL | NOR | NLD | ITA | ISR | IRL | GRC | GBR | FRA | ESP | DNK | DEU | CHE | CAN | BRA | AUS | ARG | 7 |
| NCT04183166 | Phase I | TG4050 | A Clinical Trial Evaluating TG4050 in Head and Neck Cancer | Recruiting | USA | GBR | FRA | ESP | 0 |
| NCT04193293 | Phase Ib/II | Duvelisib + Pembrolizumab | A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer | Terminated | USA | 0 |
| NCT04196283 | Phase I | ABBV-368 + IMO-2125 ABBV-368 + IMO-2125 + Nab-paclitaxel ABBV-368 + Budigalimab + IMO-2125 + Nab-paclitaxel | A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | Completed | USA | NLD | ISR | FRA | ESP | DEU | 0 |
| NCT04199104 | Phase III | Lenvatinib + Pembrolizumab Pembrolizumab | A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010) (LEAP-10) | Active, not recruiting | USA | TUR | POL | ITA | HUN | GBR | FRA | ESP | DEU | CAN | BRA | AUS | 7 |
| NCT04278092 | Phase II | Cetuximab + Paclitaxel | Paclitaxel Plus Cetuximab After First-line Checkpoint Inhibitor Failure | Recruiting | AUT | 0 |
| NCT04282109 | Phase II | Nivolumab + Paclitaxel Cetuximab + Paclitaxel | Study to Assess the Efficacy and Safety of Nivolumab in Combination With Paclitaxel in Subjects With Head and Neck Cancer Unable for Cisplatin-based Chemotherapy (NIVOTAX) (NIVOTAX) | Completed | ESP | 0 |
| NCT04290546 | Phase I | CIML-NK cells + Ipilimumab + Nogapendekin alfa inbakicept CIML-NK cells + Nogapendekin alfa inbakicept | CIML NK Cell in Head & Neck Cancer | Active, not recruiting | USA | 0 |
| NCT04428047 | Phase II | Bintrafusp alfa | Evaluation of Bintrafusp Alfa in Operable and Untreated Head and Neck Squamous Cell Carcinoma (ICING) | Terminated | FRA | 0 |
| NCT04428151 | Phase II | Lenvatinib + Pembrolizumab Docetaxel Paclitaxel Capecitabine Cetuximab Lenvatinib | Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) | Active, not recruiting | USA | ROU | NOR | ISR | GBR | FRA | ESP | DNK | CAN | BRA | AUS | 4 |
| NCT04428333 | Phase III | Carboplatin + Fluorouracil + Pembrolizumab Cisplatin + Fluorouracil + GSK3359609 + Pembrolizumab Cisplatin + Fluorouracil + Pembrolizumab Carboplatin + Fluorouracil + GSK3359609 + Pembrolizumab | Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Terminated | USA | SWE | ROU | POL | ITA | IRL | GBR | FRA | ESP | DNK | DEU | CAN | BRA | BEL | AUS | ARG | 3 |
| NCT04445064 | Phase II | IO102 IO103 | Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck. (HN1901) | Unknown status | BEL | 0 |
| NCT04453046 | Phase I | Pembrolizumab | Hemopurifier Plus Pembrolizumab in Head and Neck Cancer | Terminated | USA | 0 |
| NCT04459715 | Phase III | Cisplatin + Xevinapant Cisplatin | A Study of Xevinapant (Debio 1143) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy (TrilynX) | Terminated | USA | POL | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG | 8 |
| NCT04477759 | Phase I | Atezolizumab | Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer (DEHART) | Active, not recruiting | USA | 0 |
| NCT04521621 | Phase Ib/II | Coxsackievirus A21 + Pembrolizumab | A Study of Gebasaxturev (V937) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (V937-013) | Terminated | USA | POL | NOR | ITA | ISR | HUN | FRA | ESP | DEU | CAN | 4 |
| NCT04533750 | Phase I | Peposertib | Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin | Recruiting | USA | 0 |
| NCT04534205 | Phase II | BNT113 + Pembrolizumab Pembrolizumab | A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT) | Recruiting | USA | TUR | SWE | POL | ITA | HUN | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUT | AUS | ARG | 5 |
| NCT04576091 | Phase I | Elimusertib + Pembrolizumab | Testing the Addition of an Anti-cancer Drug, BAY1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer | Active, not recruiting | USA | 0 |
| NCT04588038 | Phase I | NT-I7 | NT-I7 for the Treatment of Recurrent Squamous Cell Carcinoma of Head and Neck Undergoing Surgery | Recruiting | USA | 0 |
| NCT04590963 | Phase III | Cetuximab Cetuximab + Monalizumab | Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer (INTERLINK-1) | Active, not recruiting | USA | POL | NLD | ITA | GRC | GBR | FRA | ESP | DEU | CHE | CAN | BRA | BGR | BEL | AUT | AUS | ARG | 6 |
| NCT04624113 | Phase Ib/II | Pembrolizumab + Tazemetostat | Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma | Terminated | USA | 0 |
| NCT04633278 | Phase II | Pembrolizumab + Vidutolimod | CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Terminated | USA | 0 |
| NCT04634825 | Phase II | MGA271 + Retifanlimab MGA271 + MGD013 | Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer | Terminated | USA | POL | HUN | ESP | BGR | AUS | 1 |
| NCT04643379 | Phase II | Carboplatin + Olaparib + Pembrolizumab Olaparib + Pembrolizumab | Olaparib in Combination With Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma | Active, not recruiting | USA | 0 |
| NCT04665843 | Phase II | Atezolizumab + Tiragolumab Atezolizumab | A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck (SKYSCRAPER-09) | Active, not recruiting | USA | POL | NZL | ITA | HUN | GRC | GBR | FRA | ESP | CZE | 3 |
| NCT04671667 | Phase II | Cisplatin Pembrolizumab Carboplatin | Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma | Recruiting | USA | 0 |
| NCT04681469 | Phase II | Dostarlimab-gxly + Niraparib | Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC (PRIME) | Recruiting | ITA | 0 |
| NCT04722523 | Phase I | Cemiplimab + Cetuximab + Cisplatin + Docetaxel Carboplatin + Cemiplimab + Cetuximab + Docetaxel | A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer | Recruiting | USA | 0 |
| NCT04747054 | Phase III | Pembrolizumab + Radiotherapy Pembrolizumab Carboplatin + Fluorouracil Cisplatin + Fluorouracil | Study on the Efficacy of Treatment by Radiotherapy and Pembrolizumab in Newly Diagnosed Metastatic Head & Neck Cancers (PembroMetaRT) | Recruiting | FRA | 0 |
| NCT04754321 | Phase I | Pembrolizumab | Pembrolizumab and Radiation Therapy Before and During Surgery for the Treatment of Persistent or Recurrent Head and Neck Cancer | Recruiting | USA | 0 |
| NCT04795713 | Phase I | MT-6402 | Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1 | Terminated | USA | 0 |
| NCT04811027 | Phase II | Eftilagimod alpha + Pembrolizumab Pembrolizumab | Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC (TACTI-003) | Active, not recruiting | USA | ROU | GBR | ESP | DNK | DEU | BEL | AUS | 1 |
| NCT04815720 | Phase Ib/II | Pembrolizumab + Pepinemab | Pepinemab in Combination With Pembrolizumab in Advanced, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE B84) | Recruiting | USA | 0 |
| NCT04830592 | Phase I | NG-641 NG-641 + Pembrolizumab | A Study of NG-641 and Pembrolizumab in Squamous Cell Carcinoma of the Head and Neck (MOAT) | Active, not recruiting | GBR | 0 |
| NCT04831320 | Phase II | Nab-paclitaxel + Nivolumab | Nab-Paclitaxel in Combination With Nivolumab to Treat Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma That Progressed on a PD-1 or PD-L1 Inhibitor | Active, not recruiting | USA | 0 |
| NCT04858269 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab | First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients | Recruiting | USA | 0 |
| NCT04862650 | Phase II | Carboplatin + Cemiplimab + Paclitaxel | Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | Suspended | USA | 0 |
| NCT04892875 | Phase I | Cisplatin + Zimberelimab Cisplatin Cisplatin + Etrumadenant + Zimberelimab | A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers (PANTHEoN) | Withdrawn | 0 | |
| NCT04925284 | Phase I | XB002 Nivolumab + XB002 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | Active, not recruiting | USA | NLD | ITA | GBR | FRA | ESP | BEL | AUS | 1 |
| NCT04958239 | Phase I | BI 765179 + Ezabenlimab BI 765179 | A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer | Recruiting | USA | NLD | ITA | ISR | FRA | ESP | DEU | CZE | BRA | BEL | AUS | 4 |
| NCT04966481 | Phase III | Cetuximab + Palbociclib Cetuximab | Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor | Recruiting | USA | 0 |
| NCT04969861 | Phase II | NKTR-214 + Pembrolizumab Pembrolizumab | BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) | Terminated | USA | ITA | GRC | AUT | 0 |
| NCT04989387 | Phase I | INCA00186 + Retifanlimab INCA00186 + INCB106385 INCA00186 + INCB106385 + Retifanlimab INCA00186 | Study of INCA 0186 in Subjects With Advanced Solid Tumors | Active, not recruiting | USA | NLD | GBR | ESP | BEL | AUT | 0 |
| NCT05053737 | Phase Ib/II | Atezolizumab | Radiotherapy in Combination With Atezolizumab Prior to Surgical Resection for HPV Unrelated HNSCC | Suspended | USA | 0 |
| NCT05057247 | Phase II | Docetaxel + Duvelisib | Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC | Active, not recruiting | USA | 0 |
| NCT05061420 | Phase II | Cetuximab + Pembrolizumab + THOR-707 Cetuximab + THOR-707 Pembrolizumab + THOR-707 | A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) | Active, not recruiting | USA | NLD | ITA | FRA | ESP | DEU | CAN | ARG | 3 |
| NCT05136196 | Phase II | Cabozantinib + Nivolumab | BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study | Suspended | USA | 0 |
| NCT05144698 | Phase II | RAPA-201 | RAPA-201 Therapy of Solid Tumors | Recruiting | USA | 0 |
| NCT05172245 | Phase I | Cisplatin + Ipatasertib | Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer | Recruiting | USA | CAN | 0 |
| NCT05172258 | Phase II | Ipatasertib + Pembrolizumab Pembrolizumab | Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck | Recruiting | USA | 0 |
| NCT05271604 | Phase II | BA3021 | A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck | Recruiting | USA | 0 |
| NCT05280314 | Phase II | IO102-IO103 + Pembrolizumab | Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab in Patients With Resectable Tumors | Recruiting | USA | FRA | ESP | DNK | DEU | AUS | 0 |
| NCT05287113 | Phase II | INCAGN02385 + Retifanlimab Retifanlimab INCAGN02385 + INCAGN02390 + Retifanlimab | Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS >= 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck | Active, not recruiting | USA | POL | NLD | ITA | GRC | FRA | ESP | DEU | CAN | BEL | 4 |
| NCT05329532 | Phase Ib/II | Modi-1 Modi-1 + Pembrolizumab | Modi-1 in Breast, Head and Neck, Ovarian, or Renal Cancer (ModiFY) | Recruiting | GBR | 0 |
| NCT05358548 | Phase II | Carboplatin + Paclitaxel + Pembrolizumab Carboplatin + Pembrolizumab + Pemetrexed Disodium Carboplatin + Fluorouracil + Pembrolizumab | ATATcH Alternating Treatment Plans for Advanced Cancer | Recruiting | USA | 0 |
| NCT05359692 | Phase II | INCAGN01876 + Retifanlimab | INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Withdrawn | USA | 0 |
| NCT05366166 | Phase II | Cisplatin + Olaparib + Pembrolizumab | Pembrolizumab Plus Olaparib in LA-HNSCC | Recruiting | USA | 0 |
| NCT05386550 | Phase III | Xevinapant | Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION) | Terminated | USA | ROU | POL | NLD | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BEL | AUT | ARG | 8 |
| NCT05414032 | Phase II | AZD2936 | Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC (MERIDIAN) | Recruiting | CAN | 0 |
| NCT05483400 | Phase II | Atezolizumab + Tiragolumab | Open Label Phase 2 Basket Trial With Atezolizumab and Tiragolumab in Solid Tumors (TIRACAN) | Recruiting | NLD | 0 |
| NCT05678348 | Phase I | Pyrimethamine | Pyrimethamine as an Inhibitor of NRF2 in HPV-unrelated Locally Advanced Head and Neck Squamous Cell Carcinoma | Recruiting | USA | 0 |
| NCT05712356 | Phase II | CEND-1 + Cisplatin + Durvalumab + Gemcitabine Cisplatin + Durvalumab + Gemcitabine Paclitaxel Docetaxel CEND-1 + Docetaxel CEND-1 + Paclitaxel | A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors (BOLSTER) | Recruiting | USA | ESP | 0 |
| NCT05721755 | Phase III | Pembrolizumab Carboplatin + Paclitaxel + Pembrolizumab Cisplatin + Fluorouracil + Pembrolizumab Carboplatin + Fluorouracil + Pembrolizumab | Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck | Recruiting | USA | 0 |
| NCT05724602 | Phase II | Xevinapant | Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (RAVINA) | Suspended | SVN | NOR | NLD | ITA | IRL | GBR | FRA | ESP | DEU | BEL | 0 |
| NCT05743270 | Phase II | Cisplatin Nivolumab Cisplatin + RP3 Carboplatin + Paclitaxel + RP3 | Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN | Withdrawn | USA | POL | GRC | GBR | FRA | ESP | DEU | CZE | 0 |
| NCT05784012 | Phase Ib/II | Dostarlimab-gxly + Niraparib Cisplatin + Dostarlimab-gxly + Niraparib | Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma (RADIAN) | Recruiting | ESP | 0 |
| NCT05814666 | Phase II | Pembrolizumab Danvatirsen + Pembrolizumab | Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC (PEMDA-HN) | Recruiting | USA | GBR | 1 |
| NCT05836324 | Phase I | INCA33890 | A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | Recruiting | USA | ITA | GBR | FRA | ESP | DNK | CHE | 0 |
| NCT05879484 | Phase Ib/II | DS-3201b + Pembrolizumab | Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS | Not yet recruiting | USA | 0 |
| NCT05909904 | Phase II | LBL-007 + Tislelizumab Tislelizumab BGB-A425 + Tislelizumab BGB-A425 + LBL-007 + Tislelizumab | Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma | Recruiting | USA | CAN | AUS | 5 |
| NCT05930938 | Phase III | Cetuximab Cetuximab + Xevinapant | Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer (XXL_2022-01) | Suspended | FRA | 0 |
| NCT05980000 | Phase II | Pembrolizumab + Ramucirumab Pembrolizumab | Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma (Rambro2) | Recruiting | USA | 0 |
| NCT05980598 | Phase II | Pembrolizumab + TransCon TLR7/8 Agonist TransCon IL-2 beta/gamma + TransCon TLR7/8 Agonist Pembrolizumab | TransCon (TC) TLR7/8 Agonist, TC IL-2 beta/gamma, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma (BelieveIT-201) | Recruiting | USA | POL | ITA | HUN | ESP | DEU | 2 |
| NCT06003231 | Phase II | Disitamab vedotin | A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 | Recruiting | USA | ITA | GBR | ESP | CAN | AUS | 1 |
| NCT06005324 | Phase I | Cisplatin Cisplatin + Fluorouracil + Hydroxyurea Carboplatin + Cetuximab + Paclitaxel | Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer | Recruiting | USA | 0 |
| NCT06016920 | Phase Ib/II | Pembrolizumab + VB10.16 | Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma | Recruiting | POL | NOR | HUN | GBR | FRA | ESP | DEU | CZE | 0 |
| NCT06046482 | Phase II | Cetuximab + Docetaxel + Hu5F9-G4 Cetuximab + Hu5F9-G4 + Pembrolizumab | Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma | Terminated | USA | 0 |
| NCT06056310 | Phase I | Cisplatin + Xevinapant Xevinapant | Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX) | Terminated | USA | ISR | ESP | BEL | 2 |
| NCT06062420 | Phase II | Dostarlimab-gxly Dostarlimab-gxly + EOS-448 + GSK6097608 Dostarlimab-gxly + GSK6097608 Dostarlimab-gxly + EOS-448 | A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202 | Recruiting | USA | TUR | ROU | POL | NOR | ITA | HUN | GRC | FRA | FIN | ESP | DNK | DEU | CAN | BRA | ARG | 4 |
| NCT06082167 | Phase II | Pembrolizumab + XL092 Pembrolizumab | Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (STELLAR-305) | Recruiting | USA | SVK | ROU | ITA | FRA | ESP | CZE | BRA | BGR | BEL | AUT | AUS | ARG | 4 |
| NCT06096038 | Phase Ib/II | iC9.CAR-CSPG4 T cells Cyclophosphamide + Fludarabine | Autologous CAR-T Cells Targeting CSPG4 in Relapsed/Refractory HNSCC | Recruiting | USA | 0 |
| NCT06110195 | Phase I | Carboplatin + Paclitaxel + Xevinapant | Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer | Active, not recruiting | USA | 0 |
| NCT06129864 | Phase III | MEDI5752 | A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC) | Recruiting | USA | TUR | POL | ITA | HUN | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUT | 8 |
| NCT06145412 | Phase II | Cisplatin + Xevinapant | A Study of Xevinapant With Cisplatin and Radiation Therapy After Surgery in People With Head and Neck Cancer | Active, not recruiting | USA | 0 |
| NCT06150664 | Phase I | CTX-8371 | A Phase 1 of CTX-8371 in Patients With Advanced Malignancies | Recruiting | USA | 0 |
| NCT06159621 | Phase I | LVGN3616 LVGN3616 + LVGN7409 | CD40 Agonist and PD-1 Inhibitor in HNSCC | Recruiting | USA | 0 |
| NCT06172478 | Phase II | Patritumab deruxtecan | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 2 |
| NCT06239220 | Phase II | Cetuximab + Nogapendekin alfa inbakicept + PD-L1.t-haNK cells | PD-L1 t-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC | Recruiting | USA | 0 |
| NCT06256588 | Phase III | Dostarlimab-gxly | A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (JADE) | Recruiting | USA | TUR | SWE | ROU | POL | NOR | ITA | ISR | HUN | GRC | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 7 |
| NCT06295731 | Phase II | INBRX-106 + Pembrolizumab Pembrolizumab | INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS>=20 HNSCC (HexAgon-HN) | Recruiting | USA | 0 |
| NCT06332092 | Phase II | Cetuximab + FID-007 | FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) | Recruiting | USA | 0 |
| NCT06357858 | Phase I | Decitabine and Cedazuridine + Nivolumab | ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck | Withdrawn | USA | 0 |
| NCT06366451 | Phase I | AZD2936 Pembrolizumab AZD7789 MEDI5752 | PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, and Sabestomig in HNSCC | Recruiting | USA | 0 |
| NCT06385080 | Phase Ib/II | Amivantamab-vmjw Amivantamab-vmjw + Pembrolizumab Amivantamab-vmjw + Paclitaxel | A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/Metastatic Head and Neck Cancer (OrigAMI-4) | Recruiting | USA | GBR | 3 |
| NCT06496178 | Phase III | Methotrexate Cetuximab Docetaxel MCLA-158 | A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients | Recruiting | USA | ISR | AUS | ARG | 3 |
| NCT06525220 | Phase III | Pembrolizumab MCLA-158 + Pembrolizumab | A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer | Recruiting | USA | ISR | AUS | ARG | 3 |
| NCT06557889 | Phase II | Carboplatin + Fluorouracil + Pembrolizumab Cisplatin + Fluorouracil + Pembrolizumab | Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas (REDUCE) | Recruiting | FRA | 0 |
| NCT06597565 | Phase II | Gemcitabine + Prexasertib | A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC | Recruiting | USA | 0 |
| NCT06636734 | Phase II | Lovastatin + Pembrolizumab | Lovastatin and Pembrolizumab for the Treatment of Patients with Recurrent or Metastatic Head and Neck Cancer, LAPP Trial | Not yet recruiting | USA | 0 |
| NCT06648096 | Phase Ib/II | Afatinib | Afatinib in Patients with Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) (AFAN) | Not yet recruiting | ESP | DEU | 0 |